Effect of the ACE inhibitor Zofenopril on the Oxidative Status of the Eye in Animals with Experimental Glaucoma

Česká verzia

Authors: Irina Mikheytseva; Serhii Kolomiichuk; Tiana T Siroshtanenko; Nataliia Storozhuk; Maxim Kuznetsov; Mayyar Alobaisi
Authors place of work: Diseases and Tissue Therapy of the National Academy of Medical Sciences, of Ukraine”, Odesa, Ukraine ; Department of Biochemistry, State Institution “The Filatov Institute of Eye
Published in the journal: Čes. a slov. Oftal., 82, 2026, No. 4, p. 205-212
Category: Původní práce
doi: https://doi.org/10.31348/2026/1

Summary

Aims: To evaluate the effect of zofenopril on oxidative stress markers and antioxidant enzyme activity in ocular tissues of rabbits with experimentally induced glaucoma.

Materials and Methods: An experimental model of adrenaline-induced glaucoma (AIG) was developed in 2–2.5-year-old rabbits. Zofenopril, an angiotensin-converting enzyme (ACE) inhibitor, was administered orally as an aqueous suspension (1 mg/kg body weight) daily for three months. Oxidative stress was assessed by measuring malondialdehyde (MDA) levels as a marker of lipid peroxidation (LPO), hydroxyl and superoxide radical generation, and the activity of antioxidant enzymes (glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase (CAT)). Intraocular pressure (IOP) in rabbits was measured using an applanation tonometer under local anesthesia with 0.5% Alcaine. Spectrophotometric analysis was performed on the retina, optic nerve, and drainage zone tissues.

Results: In the AIG modeling group, a dynamic increase in IOP was observed: by 28.3% after 30 days, by 34.2% and 46.7% after 60 and 90 days, respectively, compared to baseline data. Oral administration of zofenopril suspension during AIG modeling resulted in a milder elevation of IOP –⁠ by 17.4% on day 30 (p < 0.05) –⁠ followed by a gradual decline to 110.1% and 105.4% of baseline values on days 60 and 90, respectively. On day 90 of the study, rabbits with AIG exhibited significant activation of LPO and elevated MDA levels in ocular tissues: by 54.1% in the retina, 39.9% in the optic nerve, and 70.1% in the drainage zone, compared to controls (intact animals) (p < 0.01). Enhanced free radical generation was observed: hydroxyl radical levels increased by 71.3% in the retina, 58.9% in the optic nerve, and 81.8% in the drainage zone; superoxide radical levels increased by 78.4%, 64.4%, and 94.2%, respectively. Antioxidant enzyme activity declined in the retina, with GPx decreasing by 35.9%, SOD by 42.4%, and CAT by 30.7%, compared to the controls. Zofenopril administration during glaucoma modeling resulted in reduced MDA levels: by 19.3% in the retina, 16.1% in the optic nerve, and 28.1% in the drainage zone, compared to the untreated AIG group. Hydroxyl radical generation also decreased by 23.0% in the retina, 21.9% in the optic nerve, and 23.9% in the drainage zone. Superoxide radical levels were reduced by 20.3% in the retina and 24.9% in the drainage zone. In contrast, antioxidant enzyme activity increased in the retina: GPx rose by 33.6%, SOD by 26.2%, and CAT by 21.6%, compared to the untreated AIG group.

Conclusion: Prolonged systemic administration of zofenopril in a rabbit model of glaucoma effectively attenuated oxidative stress and stabilized intraocular pressure. Zofenopril prevented a progressive rise in IOP observed in untreated animals, maintaining IOP values close to physiological levels throughout the experiment. The treatment resulted in a marked decrease in LPO and MDA accumulation within the retina, optic nerve, and drainage zone, along with reduced generation of hydroxyl and superoxide radicals and a significant restoration of antioxidant enzyme activity.

Keywords:

glaucoma – Rabbits – Retina – Optic nerve – oxidative stress – experimental model – drainage zone tissues – ACE inhibitor zofenopril – free radical processes – antioxidant enzymes

Zdroje

1. Ban N, Siegfried CJ, Apte RS. Monitoring neurodegeneration in glaucoma: Therapeutic implications. Trends Mol Med. 2018;24(1):7 -⁠ 17.

2. Kurihara T, Ozawa Y, Ishida S, Okano H, Tsubota K. Renin-angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction. Int J Inflamm. 2012;2012 : 581695. doi:10.1155/2012/581695

3. Holappa M, Vapaatalo H, Vaajanen A. Local ocular renin-angiotensin-aldosterone system: Any connection with intraocular pressure? A comprehensive review. Ann Med. 2020;52(5):191-206. doi: 10.1080/07853890.2020.1758341

4. Shah GB, Sharma S, Mehta AA, Goyal RK. Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharmacol. 2000;36(2):169-175. doi:10.1097/00005344-200008000-00005

5. Borghi C, Omboni S. Angiotensin-converting enzyme inhibition: Beyond blood pressure control –⁠ the role of zofenopril. Adv Ther. 2020;37(10):4068-4085. doi:10.1007/s12325-020-01455-2

6. Palić B, Brizić I, Sher EK, et al. Effects of zofenopril on arterial stiffness in hypertension patients. Mol Biotechnol. 2025;67 : 3454 –⁠ 3466. doi:10.1007/s12033-023-00861-5.

7. Hurley DJ, Normile C, Irnaten M, O’Brien C. The intertwined roles of oxidative stress and endoplasmic reticulum stress in glaucoma. Antioxidants (Basel). 2022;11(5):886. doi:10.3390/antiox11050886

8. Mikheytseva I. Modeli glaukomy, preimushchestva i nedostatki. Adrenalin-indutsirovannaya glaukoma kak adekvatnaya model glaukomnogo protsessa cheloveka. Oftalmol Zh. 2011;3 : 89-92. doi:10.31288/oftalmolzh201138992

9. Mikheitseva IM. Method for modelling adrenaline-induced glaucoma in rabbits. Patent of Ukraine for utility model No. 61478. Bulletin. 2011;(14). Avaible from: https://sis.nipo.gov.ua/uk/search/ detail/246925/

10. Fedorov KN, Koivanvladimir N, et al. Modeling experimental glaucoma for screening studies of antiglaucomatous activity. Res Results Pharmacol. 2023;9(4):13-19. doi:10.18413/rrpharmacology.9.10043

11. Conte D, Narindrasorasa KS, Sarkar B. In vivo and in vitro iron-replaced zinc finger generates free radicals and causes DNA damage. Eur J Biochem. 1996;9 : 5125-5130.

12. Kuthan H, Ullrich U, Estabrook RW. A quantitative test for superoxide radicals produced in biological systems. Biochem J. 1982;203(3):551-558.

13. Orekhovich VN. Sovremennye metody v biokhimii. Moscow: Meditsina; 1977. 392 p.

14. Bou Ghanem GO, Wareham LK, Calkins DJ. Addressing neurodegeneration in glaucoma: Mechanisms, challenges, and treatments. Prog Retin Eye Res. 2024;100 : 101261. doi:10.1016/j.preteyeres.2024.101261

15. Nita M, Grzybowski A. The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. Oxid Med Cell Longev. 2016;2016 : 3164734. doi:10.1155/2016/3164734

16. Hurley DJ, Normile C, Irnaten M, O’Brien C. The intertwined roles of oxidative stress and endoplasmic reticulum stress in glaucoma. Antioxidants (Basel). 2022;11(5):886. doi:10.3390/antiox11050886

17. Nathanson JA, McKee M. Alterations of ocular nitric oxide synthase in human glaucoma. Invest Ophthalmol Vis Sci. 1995;36(9):1774 -⁠ 1784.

18. Mikheytseva I. Patogeneticheskoe znachenie endotelialnoj disfunkcii pri pervichnoj glaukome. Dosyagnennya biolohiyi medytsyny. 2009;14(2):17-20.

19. Donnarumma E, Ali M, Rushing A, Scarborough AJ. Zofenopril protects against myocardial ischemia-reperfusion injury by increasing nitric oxide and hydrogen sulfide bioavailability. J Am Heart Assoc. 2016;5(3)\:e003531. doi:10.1161/JAHA.116.003531

20. Bucci M, Vellecco V, Cantalupo A, et al. Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition. Cardiovasc Res. 2014;102(1):138-147. doi:10.1093/ cvr/cvu026

21. Nebbioso M, Franzone F, Lambiase A, et al. Oxidative stress implication in retinal diseases–a review. Antioxidants (Basel). 2022;11 : 1790. doi:10.3390/antiox11091790

22. Monti M, Terzuoli E, Ziche M, Morbidelli L. H2S dependent and independent anti-inflammatory activity of zofenoprilat in cells of the vascular wall. Pharmacol Res. 2016;113(Pt A):426-437. doi:10.1016/j.phrs.2016.09.017

23. Vaajanen A, Vapaatalo H. Local ocular renin-angiotensin systém–a target for glaucoma therapy? Basic Clin Pharmacol Toxicol. 2011;109(4):217-224. doi:10.1111/j.1742-7843.2011.00729.x

24. Holappa M, Vapaatalo H, Vaajanen A. Many faces of renin-angiotensin system—focus on eye. Open Ophthalmol J. 2017;11 : 122 -⁠ 142. doi:10.2174/1874364101711010122

25. Mitchell J, Ali F, Bailey L, Moreno L, Mackenzie L. Role of nitric oxide and prostacyclin as vasoactive hormones released by endothelium. Exp Physiol. 2008;93 : 141-147. doi:10.1113/expphysiol.2007.038588

26. Korelina V, Nagornova ZM, Seleznev A, et al. Review of herbal remedies in alternative antihypertensive and neuroprotective treatment of glaucoma. Med Biol Probl Life Act. 2024;1(31):136-148. doi:10.58708/2074-2088.2024-1(31)-136-148

27. Nakajima E, Otsugu-Kobayashi M, Uchida T, Orihara K, Shearer T, Azuma M. Calcium-dependent pathway as a primary cause of hypoxic RGC damage in monkey retinal explants. PLoS One. 2025;20:e0327246. doi:10.1371/journal.pone.0327246

28. Kwak S, Hwang S-K, Kwon M, Chun B. L-Serine protects murine retinal ganglion cells from oxidative stress via modulation of mitochondrial dysfunction. Curr Eye Res. 2024;49(7):1123-1130. doi:10.1080/02713683.2024.2355661

29. Salt T, Cordeiro M. Glutamate excitotoxicity in glaucoma. Eye (Lond). 2006;20(6):730-732. doi:10.1038/sj.eye.6701967

30. Goyal A, Srivastava A, Sihota R, Kaur J. Evaluation of oxidative stress markers in aqueous humor of primary open-angle glaucoma and primary angle-closure glaucoma patients. Curr Eye Res. 2014;39(8):823-829. doi:10.3109/02713683.2011.556299

31. Korelina VE. Study of the correction of lipid peroxidation by antioxidants in experimental glaucoma (experimental study): thesis. 1999. (in Russ.)

32. Rezapour J, Nickels S, Schuster AK, et al. Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study. BMC Ophthalmol. 2018;18(1):157. doi:10.1186/s12886-018-0831-1

33. Mendez-Ulrich JL, Sanz A, Feliu-Soler A, et al. Could White Coat Ocular Hypertension Affect the Accuracy of the Diagnosis of Glaucoma? Relationships Between Anxiety and Intraocular Pressure in a Simulated Clinical Setting. Appl Psychophysiol Biofeedback. 2018;43(1):49-56. doi:10.1007/s10484-017-9385-x

34. Otori Y, Takahashi G, Urashima M, Kuwayama Y. Evaluating the Quality of Life of Glaucoma Patients Using the State-Trait Anxiety Inventory. J Glaucoma. 2017;26(11):1025-1029. doi:10.1097/ IJG.0000000000000761

35. Korelina VE, Gazizova I, Kuroyedov A, Didur MD. Glaucoma progression during the COVID-19 pandemics. Russ J Clin Ophthalmol. 2021;21 : 147-152. doi:10.32364/2311-7729-2021-21-3-147-152